Cover Image
市場調查報告書

急性失償心臟衰竭:流行病學、病患人數的市場預測、治療流程、已上市及開發中的藥物分析

Acute decompensated heart failure: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365171
出版日期 內容資訊 英文 121 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
急性失償心臟衰竭:流行病學、病患人數的市場預測、治療流程、已上市及開發中的藥物分析 Acute decompensated heart failure: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年03月01日 內容資訊: 英文 121 Pages
簡介

新的血管擴張劑的Reasanz及ularitide,通用化發展,隱藏著再活化已成熟的急性失償心臟衰竭 (ADHF)的市場的可能性。

本報告提供急性失償心臟衰竭治療藥趨勢調查,市場定義和概要,疾病定義與診斷,處方趨勢,主要的已上市產品簡介,開發後期的開發平台趨勢等彙整資料。

預測:急性失償心臟衰竭

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • Reasanz (serelaxin)
  • Simdax (levosimendan)
  • Ularitide
  • 主要調查技術

治療:急性失償心臟衰竭

  • 摘要整理
  • 主要調查技術
  • 疾病定義與診斷
  • 各國治療樹
  • 處方趨勢

流行病學:急性失償心臟衰竭

  • 摘要整理
  • 資訊來源、調查手法
  • 預測
  • 流行病學者分析

已上市藥物:急性失償心臟衰竭

  • 摘要整理
  • 產品概要
  • 產品簡介:Natrecor
  • 產品簡介:Simdax

開發平台:急性失償心臟衰竭

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (開發後期):Reasanz
  • 產品簡介 (開發後期):ularitide

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC13163

Novel vasodilators Reasanz and ularitide have the potential to revitalize the widely genericized and mature acute decompensated heart failure (ADHF) market.

This report addresses the following questions:

  • Which launches will have the largest impact on ADHF's market sales?
  • What are the most commonly prescribed therapies for ADHF and how will the approval of new vasodilators affect ADHF's treatment dynamics?
  • How will Natrecor and Simdax be positioned in the market following the approval of new vasodilator agents?
  • What is the potential for Novartis's Reasanz and Cardiorentis's ularitide as vasodilators, considering their latest outcomes data?

TABLE OF CONTENTS

FORECAST: ACUTE DECOMPENSATED HEART FAILURE

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Reasanz (serelaxin)
  • 5. Simdax (levosimendan)
  • 6. Ularitide
  • 7. Primary Research Methodology

TREATMENT: ACUTE DECOMPENSATED HEART FAILURE

  • 8. Executive Summary
  • 9. Primary Research Methodology
  • 10. Disease Definition and Diagnosis
  • 11. Country Treatment Trees
  • 12. Prescribing Trends

EPIDEMIOLOGY: ACUTE DECOMPENSATED HEART FAILURE

  • 13. Executive Summary
  • 14. Sources and Methodology
  • 15. Forecast
  • 16. Epidemiologist Insight
  • 17. Strengths and Limitations

MARKETED DRUGS: ACUTE DECOMPENSATED HEART FAILURE

  • 18. Executive Summary
  • 19. Product Overview
  • 20. Product profile: Natrecor
  • 21. Product profile: Simdax

PIPELINE: ACUTE DECOMPENSATED HEART FAILURE

  • 22. Executive Summary
  • 23. Clinical Pipeline Overview
  • 24. Product profile (late stage): Reasanz
  • 24. Product profile (late stage): ularitide
Back to Top